1.A Paragonimiasis Patient with Allergic Reaction to Praziquantel and Resistance to Triclabendazole: Successful Treatment after Desensitization to Praziquantel.
Sun Young KYUNG ; Yong Kyun CHO ; Yu Jin KIM ; Jeong Woong PARK ; Sung Hwan JEONG ; Jae Ik LEE ; Yon Mi SUNG ; Sang Pyo LEE
The Korean Journal of Parasitology 2011;49(1):73-77
Paragonimiasis is an infectious disease caused by trematodes of the genus Paragonimus. This trematode can be treated successfully with praziquantel in more than 90% of the cases. Although praziquantel is generally well tolerated, anaphylactic reactions to this drug have been reported in a few cases. We report here a 46-year-old Korean female with paragonimiasis, presumed to be due to Paragonimus westermani, who displayed an allergic reaction to praziquantel and resistance to triclabendazole treatment. The patient was successfully treated with praziquantel following a rapid desensitization procedure. Desensitization to praziquantel could be considered when no alternative drugs are available.
Animals
;
Benzimidazoles/*therapeutic use
;
*Desensitization, Immunologic
;
Drug Hypersensitivity/etiology/immunology/*therapy
;
*Drug Resistance
;
Female
;
Humans
;
Middle Aged
;
Paragonimiasis/*drug therapy/immunology/parasitology
;
Paragonimus/isolation & purification/physiology
;
Praziquantel/*adverse effects/*immunology/therapeutic use
;
Treatment Outcome
2.Side effects and strategy in treating pediatric patients with aplastic anemia with anti-thymocyte globulin.
Wei WU ; He-ping SHEN ; Fen-ying ZHAO
Chinese Journal of Pediatrics 2006;44(5):383-384
Adolescent
;
Anemia, Aplastic
;
drug therapy
;
immunology
;
Antilymphocyte Serum
;
administration & dosage
;
adverse effects
;
Child
;
Child, Preschool
;
Drug Hypersensitivity
;
etiology
;
Female
;
Humans
;
Immunosuppressive Agents
;
administration & dosage
;
adverse effects
;
Infant
;
Male
;
Retrospective Studies
;
Serum Sickness
;
chemically induced
;
T-Lymphocytes
;
immunology
;
Treatment Outcome
3.Improvement in Erythropoieis-stimulating Agent-induced Pure Red-cell Aplasia by Introduction of Darbepoetin-alpha When the Anti-erythropoietin Antibody Titer Declines Spontaneously.
Hajeong LEE ; Jaeseok YANG ; Hyosang KIM ; Ju Won KWON ; Kook Hwan OH ; Kwon Wook JOO ; Yon Su KIM ; Curie AHN ; Jin Suk HAN ; Suhnggwon KIM
Journal of Korean Medical Science 2010;25(11):1676-1679
Anti-erythropoietin antibodies usually cross-react with all kinds of recombinant erythropoietins; therefore, erythropoiesis-stimulating agent (ESA)-induced pure red-cell aplasia (PRCA) is not rescued by different ESAs. Here, we present a case of ESA-induced PRCA in a 36-yr-old woman with chronic kidney disease, whose anemic condition improved following reintroduction of darbepoetin-alpha. The patient developed progressive, severe anemia after the use of erythropoietin-alpha. As the anemia did not improve after the administration of either other erythropoietin-alpha products or erythropoietin-beta, all ESAs were discontinued. Oxymetholone therapy failed to improve the transfusion-dependent anemia and a rechallenge with ESAs continuously failed to obtain a sustained response. However, her anemia improved following reintroduction of darbepoetin-alpha at 3 yr after the initial diagnosis. Interestingly, anti-erythropoietin antibodies were still detectable, although their concentration was too low for titration. In conclusion, darbepoetin-alpha can improve ESA-induced PRCA when the anti-erythropoietin antibody titer declines and its neutralizing capacity is lost.
Adult
;
Anemia/drug therapy/etiology
;
Antibodies/*blood/immunology
;
Bone Marrow Cells/pathology
;
Drug Hypersensitivity/immunology
;
Erythropoietin/*analogs & derivatives/therapeutic use
;
Erythropoietin, Recombinant/adverse effects/*immunology/therapeutic use
;
Female
;
Glomerulonephritis, IGA/complications
;
Hematinics/adverse effects/immunology/*therapeutic use
;
Humans
;
Kidney Failure, Chronic/complications
;
Oxymetholone/therapeutic use
;
Red-Cell Aplasia, Pure/chemically induced/*drug therapy/immunology